Innovation Pharmaceuticals Inc (IPIX)

[joseytheoutlawwales]

Not necessarily, a ‘development’ could be a delay in trial start due to local IRB wanting more safety info.
Could be a delay in trial patient availability.
Could be a delay in getting B to trial sites.
Could be a catastrophic failure of B with a fatality that halted the trial (unlikely given B’s known safety profile across multiple trials).

I say these, as there are several more as well, and each can be listed as a material ‘development’ that requires “rewording” the filing.